New findings published in 2013 strongly support the use of novel oral anticoagulants in the treatment of thromboembolic disorders. These drugs have been shown to have a more-favourable benefit-to-risk profile than older compounds, enabling their use from the start of treatment and in the whole spectrum of clinical presentations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Agnelli, G. et al. Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 369, 799–808 (2013).
Bauersachs, R. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363, 2499–2510 (2010).
Büller, H. R. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366, 1287–1297 (2012).
Agnelli, G. et al. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. 368, 699–708 (2013).
Schulman, S. et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med. 368, 709–718 (2013).
Schulman, S. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342–2352 (2009).
Prandoni, P. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients. Haematologica 92, 199–205 (2007).
Büller, H. R. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. 369, 1406–1415 (2013).
Konstantinides, S. & Goldhaber, S. Z. Pulmonary embolism: risk assessment and management. Eur. Heart J. 33, 3014–3022 (2012).
Prandoni, P., Barbar, S., Milan, M., Vedovetto, V. & Pesavento, R. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities. Eur. J. Intern. Med. http://dx.doi.org/10.1016/j.ejim.2013.09.005.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares associations with the following companies: Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer.
Rights and permissions
About this article
Cite this article
Prandoni, P. The advent of the novel oral anticoagulants. Nat Rev Cardiol 11, 70–72 (2014). https://doi.org/10.1038/nrcardio.2013.210
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.210
This article is cited by
-
The value of inhibitors of factor Xa for the treatment of pulmonary embolism
Internal and Emergency Medicine (2014)
